Hengrui Pharma – Talk Bio

Actionable Insights Powered by AI

Glenmark Pharma Signs $1.1 Billion Deal with Hengrui for HER2-Targeted Antibody-Drug Conjugate

2 weeks ago talkbio0Tagged Cancer Therapeutic Procedure, Glenmark, Hengrui Pharma, HER2-targeting antibody drug conjugate, License, milestone payments, Neoplasms, royalties, Trastuzumab Rezetecan

Glenmark; Hengrui Pharma; Trastuzumab Rezetecan; HER2-targeting antibody drug conjugate; oncology; exclusive license; $1.1 billion deal; cancer therapy; milestone payments; royalties

GSK Strengthens COPD Offering via $12 Billion Multi-Program Deal with China’s Hengrui Pharma

2 months ago talkbio0Tagged biobucks, COPD, Hengrui Pharma, HRS-9821, Immunology, Licensing, Neoplasms, Nucala, PDE3/4 inhibitor, SmithKline Beecham

GSK; Hengrui Pharma; COPD; biobucks; PDE3/4 inhibitor; HRS-9821; Nucala; immunology; oncology; licensing deal